| Business Summary | | Discovery
Laboratories
Inc.
(DLI)
is
a
development
stage
pharmaceutical
company
that
focuses
on
developing
compounds
to
treat
respiratory
diseases
that
affect
the
ability
of
the
lungs
to
absorb
oxygen.
DLI
is
initially
developing
its
lead
product
candidate,
Surfaxin,
for
use
by
newborn
infants
to
treat
two
respiratory
conditions
in
critical
care
units
of
hospitals.
The
Company
is
also
developing
this
lead
product
candidate
for
the
treatment
of
acute
respiratory
distress
syndrome
in
adult
patients
and
acute
lung
injury
in
adult
patients.
The
Company
believes
it
can
use
other
formulations
of
Surfaxin
or
its
proprietary
synthetic
peptide,
sinapultide,
to
treat
other
respiratory
conditions.
These
include
asthma
and
chronic
obstructive
pulmonary
disease.
In
addition,
the
Company
believes
it
can
use
Surfaxin
to
deliver
drugs
that
are
currently
delivered
orally
or
by
injection.
These
drugs
include
antibiotics,
pulmonary
vasodilators,
bronchodilators,
steroids
and
proteins. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Discovery
Laboratories
is
a
development
stage
pharmaceutical
company
that
is
focused
on
developing
compounds
to
treat
respiratory
diseases
that
affect
the
ability
of
the
lungs
to
absorb
oxygen.
For
the
six
months
ended
6/30/01,
revenues
totalled
$1.4
million,
up
from
$337
thousand.
Net
loss
fell
2%
to
$4.4
million.
Revenues
reflect
increased
research
grants,
interest,
and
realized
gains.
Lower
loss
reflects
a
decrease
in
compensatory
stock
option
charges. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Herbert McDade, Jr., 74 Chairman | -- | -- | Robert Capetola, Ph.D., 51 Pres,
CEO, | $386K | $246K | Christopher Schaber, 34 COO,
Exec. VP of Drug Devel. and Regulatory Compliance | 270K | 680K | Deni Zodda, Ph.D, 47 Sr.
VP, Bus. Devel. | -- | -- | Evan Myrianthopoulos, 36 VP-Fin. | 180K | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|